Literature DB >> 2828746

Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in vivo.

N Ura1, O A Carretero, E G Erdös.   

Abstract

The relative contributions of three kininases to total urinary kininase activity were determined by measuring the hydrolysis of kinins in the presence and absence of inhibitors of kininase I (2-mercaptomethyl-3-guanidinoethylthiopropanoic acid; MGTA), kininase II (captopril) and neutral endopeptidase 24.11 (NEP or enkephalinase A; phosphoramidon). Surprisingly, NEP was responsible for 68 +/- 2% (N = 18) of the total kininase in the rat while kininase I and II contributed only 9 +/- 0.4% and 23 +/- 1%, respectively. To study the effects of NEP inhibition on renal function, phosphoramidon (110 or 330 micrograms/hr/kg; N = 6) or saline (0.1 microliter/min; N = 6) was infused into rats. Urinary kinins, kininases, renal blood flow (RBF), glomerular filtration rate (GFR), UNaV, UKV and UV were measured during control, experimental and recovery periods. Phosphoramidon at the higher dose decreased total urinary kininase activity from 284 +/- 49 to 58 +/- 5 ng/min/kg (77%, P less than 0.01), and increased kinin excretion from 74 +/- 9 to 128 +/- 21 pg/min/kg (73%, P less than 0.02), UV from 72 +/- 10 to 82 +/- 10 microliters/min/kg (15%, P less than 0.01) and UNaV from 12 +/- 2 to 17 +/- 3 microEq/min/kg (37%, P less than 0.02), while BP, RBF, GFR and UKV did not change. 125I-Tyr0-bradykinin infused into the aorta did not appear in the urine intact during simultaneous phosphoramidon and captopril administration. This is the first demonstration of NEP having a major role in the catabolism of kinins. The increase in UNaV and UV after phosphoramidon administration may be due to the inhibition of intrarenal kinin destruction.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2828746     DOI: 10.1038/ki.1987.239

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  20 in total

Review 1.  Role of bradykinin in preconditioning and protection of the ischaemic myocardium.

Authors:  G F Baxter; Z Ebrahim
Journal:  Br J Pharmacol       Date:  2002-02       Impact factor: 8.739

2.  Reduction of sodium deoxycholic acid-induced scratching behaviour by bradykinin B2 receptor antagonists.

Authors:  I Hayashi; M Majima
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

Review 3.  Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: insights from experimental heart failure.

Authors:  H H Chen; A Cataliotti; J C Burnett
Journal:  Curr Hypertens Rep       Date:  2001-12       Impact factor: 5.369

4.  Molecular cloning and biochemical characterization of a new mouse testis soluble-zinc-metallopeptidase of the neprilysin family.

Authors:  G Ghaddar; A F Ruchon; M Carpentier; M Marcinkiewicz; N G Seidah; P Crine; L Desgroseillers; G Boileau
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

Review 5.  Localization and regulation of the renal kallikrein kinin system: possible relations to renal transport functions.

Authors:  W G Guder; J Hallbach
Journal:  Klin Wochenschr       Date:  1988-09-15

6.  Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.

Authors:  M C Fournié-Zaluski; W Gonzalez; S Turcaud; I Pham; B P Roques; J B Michel
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

7.  Altered renal kallikrein and renin gene expression in nephrotic rats and modulation by converting enzyme inhibition.

Authors:  F N Hutchison; S K Webster; A A Jaffa
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

8.  Renal tubular responsiveness to atrial natriuretic peptide in sodium-retaining chronic caval dogs. A possible role for kinins and luminal actions of the peptide.

Authors:  L Legault; P Cernacek; M Levy; E Maher; D Farber
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

9.  Pulmonary and urinary clearance of atrial natriuretic factor in acute congestive heart failure in dogs.

Authors:  M A Perrella; K B Margulies; C M Wei; L L Aarhus; D M Heublein; J C Burnett
Journal:  J Clin Invest       Date:  1991-05       Impact factor: 14.808

10.  Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): rational design, properties, and potential cardiovascular applications of glycopril and alatriopril.

Authors:  C Gros; N Noël; A Souque; J C Schwartz; D Danvy; J C Plaquevent; L Duhamel; P Duhamel; J M Lecomte; J Bralet
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.